Please login to the form below

Immuno-oncology: The market opportunity for PD-1/PD-L1s


Immuno-oncology is the new frontier in cancer treatment. Using the body’s own immune system to treat cancer, new therapies are producing impressive survival benefits, with reduced side effects. Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1 market at this time.

http://www.researchpartnership.com/news/2016/08/infographic-immunno-oncology/

23rd November 2016

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

A safe place to talk about Crohn’s
Published in eyeforpharma April 2017 by Mariel Metcalfe
Research Partnership
Patient Assistance Programme Evaluation for Cardiovascular Conditions

Research Partnership
What next for the treatment of Psoriasis in Europe?
Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.
Research Partnership
20 questions: Round 1

Research Partnership
Brand tracking research

Research Partnership
Pharma China Annual Forum 2017
We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.
Research Partnership